Safety, tolerability, and immunogenicity of a recombinant, genetically engineered, live-attenuated vaccine against canine blastomycosis

Clinical and Vaccine Immunology

Volumn 18, Issue 5, 2011, Pages 783-789

  Wüthrich, Marcel ^a   Krajaejun, Theerapong ^a   Shearn Bochsler, Valerie ^b   Bass, Chris ^c   Filutowicz, Hanna I ^a   Legendre, Alfred M ^c   Klein, Bruce S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGUS VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIVE VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLASTOMYCES DERMATITIDIS; BLASTOMYCOSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOG; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNGAL STRAIN; GENETIC TRANSCRIPTION; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; BLASTOMYCES; BLASTOMYCOSIS; BLOOD; DOG DISEASES; DOGS; FEMALE; FUNGAL VACCINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; MALE; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRULENCE FACTORS;

EID: 79955731583     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00560-10     Document Type: Article

References (13)

1. Allendorfer, R., G. D. Brunner, and G. S. Deepe, Jr. 1999. Complex requirements for nascent and memory immunity in pulmonary histoplasmosis. J. Immunol. 162:7389-7396.
2. Baumgardner, D. J., D. P. Paretsky, and A. C. Yopp. 1995. The epidemiology of blastomycosis in dogs: north central Wisconsin, U. S. A. J. Med. Vet. Mycol. 33:171-176.
3. Brandhorst, T. T., M. Wüthrich, T. Warner, and B. Klein. 1999. Targeted gene disruption reveals an adhesin indispensable for pathogenicity of Blastomyces dermatitidis. J. Exp. Med. 189:1207-1216.
4. Fisher, L. D., and G. van Belle. 1993. Biostatistics: a methodology for the health sciences, p. 611-613. John Wiley & Sons, New York, NY.
5. Harvey, R. P., E. S. Schmid, C. C. Carrington, and D. A. Stevens. 1978. Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters. Am. Rev. Respir. Dis. 117:695-703.
6. Johnson, M. R., K. Wang, J. B. Smith, M. J. Heslin, and R. B. Diasio. 2000. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal. Biochem. 278:175-184.
7. Klein, B. S., and J. M. Jones. 1990. Isolation, purification, and radiolabeling of a novel 120-kD surface protein on Blastomyces dermatitidis yeasts to detect antibody in infected patients. J. Clin. Invest. 85:152-161.
8. Klein, B. S., R. A. Squires, J. K. Lloyd, D. R. Ruge, and A. M. Legendre. 2000. Canine antibody response to Blastomyces dermatitidis WI-1 antigen. Am. J. Vet. Res. 61:554-558.
9. Legendre, A. M. 2006. Blastomycosis. Saunders Elsevier, St. Louis, MO.
10. Wüthrich, M., H. I. Filutowicz, and B. S. Klein. 2000. Mutation of the WI-1 gene yields an attenuated Blastomyces dermatitidis strain that induces host resistance. J. Clin. Invest. 106:1381-1389.
11. Wüthrich, M., H. I. Filutowicz, T. Warner, G. S. Deepe, Jr., and B. S. Klein. 2003. Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J. Exp. Med. 197:1405-1416.
12. Wüthrich, M., H. I. Filutowicz, T. Warner, and B. S. Klein. 2002. Requisite elements in vaccine immunity to Blastomyces dermatitidis: plasticity uncovers vaccine potential in immune-deficient hosts. J. Immunol. 169:6969-6976.
13. Wüthrich, M., et al. 2011. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J. Clin. Invest. 121:554-568.